Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

houtx1 Jul. 17 at 3:46 PM

$SNGX A move above 1.40 that hold, should attract new buyers.

0 · Reply

Stmkr Jul. 16 at 7:31 PM

$SNGX This seems extremely beaten down. Reversal from here? Still short cash runway but decent catalysts within runway

0 · Reply

JarvisFlow Jul. 16 at 1:23 PM

Alliance Global Partners updates rating for Soligenix ( $SNGX ) to Buy, target set at 10 → 6.

0 · Reply

NetworkNewsWire Jul. 15 at 7:12 PM

BioMedNewsBreaks – Zacks Research Releases Updated Report as $SNGX Eyes Upcoming ‘Key Catalysts’ https://ibn.fm/F01l2

0 · Reply

Bpro204 Jul. 14 at 4:12 PM

$SNGX anyone know financials? Cash on hand and current burn rate?

1 · Reply

rrch Jul. 14 at 3:20 PM

$SNGX I think this will now move much higher. 2 major catalysts this quarter and only 3 million shares outstanding. Possible partner announcement

0 · Reply

Vote4Pedro2 Jul. 11 at 10:12 PM

$INKT $SNGX is next. Only 3.4 million in supply $INKT is 3.9

0 · Reply

NetworkNewsWire Jul. 11 at 5:17 PM

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases $SNGX https://ibn.fm/h2eXP #biomedstocks #InfectiousDiseases

0 · Reply

InsaneTang Jul. 11 at 11:04 AM

$SNGX Tick tock... $SNGX has multiple catalysts lining up in the second half of 2025. Phase 3 FLASH2 trial for HyBryte (CTCL) with an enrollment update expected soon Investigator study showed 75% success rate after 18 weeks of treatment Phase 2a psoriasis trial results expected in Q4 Behcet’s disease trial results expected in Q3 U.S.-based manufacturing of synthetic hypericin now in place Zacks has a $35 valuation target while the stock trades near $1.25. The pipeline potential is not priced in. Low float. High upside.

0 · Reply

counter Jul. 11 at 2:23 AM

$SNGX this is the monthly chart...has anyone ever noticed, ANYTIME price has gone OVER the blue line (arrow pointing to) price has fallen to try get back to it...coincidence? I dont think so...its like a planned move from inception...at that low dollar area, i know how they love to try hammer these stocks below so theyre out of compliance...pitch how soon to see some kind of news (and i mean real news)

0 · Reply

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 16 days ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 5 weeks ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 2 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 3 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 4 months ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 4 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 5 months ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 6 months ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 6 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 7 months ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 8 months ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 8 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 8 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 8 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 8 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 9 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 9 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 10 months ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 10 months ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 10 months ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 10 months ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 11 months ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 14, 2024, 7:30 AM EDT - 1 year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Jun 7, 2024, 9:00 AM EDT - 1 year ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

STSS

May 31, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Reverse Stock Split

May 29, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 24, 2024, 7:30 AM EDT - 1 year ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 23, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 21, 2024, 7:30 AM EDT - 1 year ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 20, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 16, 2024, 7:30 AM EDT - 1 year ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 10, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

May 6, 2024, 7:30 AM EDT - 1 year ago

Soligenix to Present at Upcoming Conferences

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Soligenix Announces Pricing of $4.75 Million Public Offering

Apr 15, 2024, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Apr 11, 2024, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

Mar 15, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

houtx1 Jul. 17 at 3:46 PM

$SNGX A move above 1.40 that hold, should attract new buyers.

0 · Reply

Stmkr Jul. 16 at 7:31 PM

$SNGX This seems extremely beaten down. Reversal from here? Still short cash runway but decent catalysts within runway

0 · Reply

JarvisFlow Jul. 16 at 1:23 PM

Alliance Global Partners updates rating for Soligenix ( $SNGX ) to Buy, target set at 10 → 6.

0 · Reply

NetworkNewsWire Jul. 15 at 7:12 PM

BioMedNewsBreaks – Zacks Research Releases Updated Report as $SNGX Eyes Upcoming ‘Key Catalysts’ https://ibn.fm/F01l2

0 · Reply

Bpro204 Jul. 14 at 4:12 PM

$SNGX anyone know financials? Cash on hand and current burn rate?

1 · Reply

rrch Jul. 14 at 3:20 PM

$SNGX I think this will now move much higher. 2 major catalysts this quarter and only 3 million shares outstanding. Possible partner announcement

0 · Reply

Vote4Pedro2 Jul. 11 at 10:12 PM

$INKT $SNGX is next. Only 3.4 million in supply $INKT is 3.9

0 · Reply

NetworkNewsWire Jul. 11 at 5:17 PM

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases $SNGX https://ibn.fm/h2eXP #biomedstocks #InfectiousDiseases

0 · Reply

InsaneTang Jul. 11 at 11:04 AM

0 · Reply

counter Jul. 11 at 2:23 AM

0 · Reply

ZacksSCR Jul. 10 at 4:21 PM

$SNGX: Multiple Catalysts Upcoming in 2H25… https://buff.ly/gJkKtpi

0 · Reply

birdsong9 Jul. 10 at 3:11 PM

$SNGX buy

0 · Reply

houtx1 Jul. 10 at 2:15 PM

$SNGX Im expecting more buyers to begin showing up if this can hold at 1.31 and above. So far bullish interest is popping up. Jmo

0 · Reply

houtx1 Jul. 10 at 2:00 PM

$SNGX shorts are trying to keep this below 1.30. If bulls can take them out, good sign. Sellers at 1.35 and 1.40.

0 · Reply

NetworkNewsWire Jul. 9 at 5:15 PM

BioMedNewsBreaks – $SNGX Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline https://ibn.fm/297rr

0 · Reply

S2K_TradeZ Jul. 9 at 2:54 PM

$SNGX long swing idea. HTB. Short squeeze candidate. MC is only 4M. More positive PRs to come for sure! 🚨🔥

0 · Reply

houtx1 Jul. 9 at 2:28 PM

$SNGX a move above 1.30 would break above the consolidation on the one hour chart since july 2. Seems like tbis is improving. Lets see

0 · Reply

houtx1 Jul. 9 at 1:38 PM

$SNGX looks good! Sellers at 1.45

0 · Reply

Vote4Pedro2 Jul. 9 at 10:37 AM

$SNGX Who's able to sell this in the pre-market?

0 · Reply

FeliciaMath Jul. 8 at 11:48 PM

bought $SNGX at 1.22 today

0 · Reply

houtx1 Jul. 8 at 3:58 PM

$SNGX A 5k seller just arrived at 1.30. Lets see if he chickens out or gets absorbed. Really nice buy volume at 1.28.

0 · Reply

ItTakesItAll Jul. 8 at 2:59 PM

$SNGX Adding little by little 1.10-1.20s, oversold, undervalued.

1 · Reply

Market Cap	4.08M
Revenue (ttm)	120,000.00
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,891.67%
Debt to Equity Ratio	0.00

Volume	118,200
Avg Vol	1,104,604
Day's Range	N/A - N/A
Shares Out	3.26M
Stochastic %K	80%
Beta	1.87
Analysts	Strong Buy
Price Target	$22.50